Between 2022 and 2025, AstraZeneca experienced strong revenue expansion coupled with accelerated net income growth, underpinned by strategic innovation investments and patent protection. The company’s well-diversified geographic footprint and solid R&D pipeline bolster its prospects despite ongoing regulatory and competitive challenges. AstraZeneca maintains disciplined capital allocation focused on sustaining R&D while ensuring stable shareholder returns, with a return on equity near 21%. Investors should monitor upcoming pipeline readouts, patent expirations, and guidance updates for directional insights.